387
edits
Changes
Created page with '{{Drugcombi | base = valproic acid | add = olanzapine | info = * Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic a...'
{{Drugcombi
| base = valproic acid
| add = olanzapine
| info =
* Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.
* Olanzapine is principally metabolized by CYP1A2 and CYP2D6.
| start =
* Start olanzapine according to the general dosing advice. Monitoring of the liver function every 3 to 4 months during the first year of treatment with either olanzapine or valproic acid is recommended.<ref name="drugscom">{{DRUGSCOM|olanzapine}}</ref>
| cave =
* Concurrent use of olanzapine and valproic acid may potentiate the risk of hepatotoxicity. <ref name="drugscom">{{DRUGSCOM|olanzapine}}</ref>
}}
| base = valproic acid
| add = olanzapine
| info =
* Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.
* Olanzapine is principally metabolized by CYP1A2 and CYP2D6.
| start =
* Start olanzapine according to the general dosing advice. Monitoring of the liver function every 3 to 4 months during the first year of treatment with either olanzapine or valproic acid is recommended.<ref name="drugscom">{{DRUGSCOM|olanzapine}}</ref>
| cave =
* Concurrent use of olanzapine and valproic acid may potentiate the risk of hepatotoxicity. <ref name="drugscom">{{DRUGSCOM|olanzapine}}</ref>
}}
